References:
1. De Waele L, Van Gaal P-J, Abramowicz D. Electrolytes disturbances
after kidney transplantation. Acta Clinica Belgica
2019;74 (1):48-52
2. Jones J, Gruessner R, Gores P, Matas AJ. Hypoaldosteronemic
hyporeninemic hyperkalemia after renal transplantation. Transplantation
1993;56 (4):1013-15
3. Kaplan B, Wang Z, Abecassis MM, Fryer JP, Stuart FP, Kaufman DB.
Frequency of hyperkalemia in recipients of simultaneous pancreas and
kidney transplants with bladder drainage. Transplantation
1996;62 (8):1174-75
4. Alfonzo AV, Isles C, Geddes C, Deighan C. Potassium
disorders—clinical spectrum and emergency management. Resuscitation
2006;70 (1):10-25
5. Davis T, Young B, Eisenberg M, Rea T, Copass M, Cobb L. Outcome of
cardiac arrests attended by emergency medical services staff at
community outpatient dialysis centers. Kidney international
2008;73 (8):933-39
6. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease.
Nature Reviews Nephrology 2014;10 (11):653
7. Pochineni V, Rondon-Berrios H. Electrolyte and acid-base disorders in
the renal transplant recipient. Frontiers in medicine
2018;5 :261
8. Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna
E, Caravaca F. Association of hyperkalemia with clinical outcomes in
advanced chronic kidney disease. Nefrología (English Edition)
2019;39 (5):513-22
9. Thomsen RW, Nicolaisen SK, Hasvold P, et al. Elevated potassium
levels in patients with chronic kidney disease: occurrence, risk factors
and clinical outcomes—a Danish population-based cohort study.
Nephrology Dialysis Transplantation 2018;33 (9):1610-20
10. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve
Clin J Med 2017;84 (12):934-42
11. Higgins R, Ramaiyan K, Dasgupta T, et al. Hyponatraemia and
hyperkalaemia are more frequent in renal transplant recipients treated
with tacrolimus than with cyclosporin. Further evidence for differences
between cyclosporin and tacrolimus nephrotoxicities. Nephrology Dialysis
Transplantation 2004;19 (2):444-50
12. Menegussi J, Tatagiba LS, Vianna JGP, Seguro AC, Luchi WM. A
physiology-based approach to a patient with hyperkalemic renal tubular
acidosis. Brazilian Journal of Nephrology 2018;40 (4):410-17
13. Heering P, Kurschat C, Vo D, Klein‐Vehne N, Fehsel K, Ivens K.
Aldosterone resistance in kidney transplantation is in part induced by a
down‐regulation of mineralocorticoid receptor expression 1. Clinical
transplantation 2004;18 (2):186-92
14. Deppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombès
M. Cyclosporine a and FK506 inhibit transcriptional activity of the
human mineralocorticoid receptor: a cell-based model to investigate
partial aldosterone resistance in kidney transplantation. Endocrinology
2002;143 (5):1932-41
15. Farouk SS, Rein JL. The Many Faces of Calcineurin Inhibitor
Toxicity—What the FK? Advances in Chronic Kidney Disease
2020;27 (1):56-66
16. Choi MJ, Fernandez PC, Patnaik A, et al. Trimethoprim-induced
hyperkalemia in a patient with AIDS. New england journal of medicine
1993;328 (10):703-06
17. Shin J-I, Palta M, Djamali A, Kaufman DB, Astor BC. The association
between renin-angiotensin system blockade and long-term outcomes in
renal transplant recipients: The Wisconsin Allograft Recipient Database
(WisARD). Transplantation 2016;100 (7):1541-49
18. Beccari MV, Meaney CJ. Clinical utility of patiromer, sodium
zirconium cyclosilicate, and sodium polystyrene sulfonate for the
treatment of hyperkalemia: an evidence-based review. Core Evidence
2017;12 :11
19. K/DOQI, National Kidney Foundation Clinical Practice Guidelines for
nutrition in chronic renal failure. Am K Kidney Disease 2000; 35:
S1-S140.
20. Nutrition for the post–renal transplant recipients. Transplantation
proceedings; 2004. Elsevier.
21. Weaver CM. Potassium and health. Advances in Nutrition
2013;4 (3):368S-77S
22. Hoffman BF, Suckling E. Effect of several cations on transmembrane
potentials of cardiac muscle. American Journal of Physiology-Legacy
Content 1956;186 (2):317-24
23. Clase CM, Carrero J-J, Ellison DH, et al. Potassium homeostasis and
management of dyskalemia in kidney diseases: conclusions from a Kidney
Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney international 2020;97 (1):42-61
24. Semple P, Both C. Calcium chloride; a reminder. Anaesthesia
1996;51 (1):93-93
25. Ringer S. A further contribution regarding the influence of the
different constituents of the blood on the contraction of the heart. The
Journal of physiology 1883;4 (1):29
26. Winkler AW, Hoff HE, Smith PK. Factors affecting the toxicity of
potassium. American Journal of Physiology-Legacy Content
1939;127 (3):430-36
27. Chamberlain M. Emergency treatment of hyperkalaemia. The Lancet
1964;283 (7331):464-67
28. Batterink J, Cessford TA, Taylor RA. Pharmacological interventions
for the acute management of hyperkalaemia in adults. Cochrane Database
of Systematic Reviews 2015(10)
29. Truhlář A, Deakin CD, Soar J, et al. European resuscitation council
guidelines for resuscitation 2015: section 4. Cardiac arrest in special
circumstances. 2015
30. Calcium Gluconate [package insert]. Lake Zurich, IL: Fresenius
Kabi; 2017.
31. Lane X, Montoliu J, Cases A, Campistol J, Revert L. Treatment of
hyperkalaemia in renal failure: salbutamol v. insulin. Nephrology
Dialysis Transplantation 1989;4 (3):228-32
32. Allon M, Copkney C. Albuterol and insulin for treatment of
hyperkalemia in hemodialysis patients. Kidney international
1990;38 (5):869-72
33. Peacock WF, Rafique Z, Clark CL, et al. Real World Evidence for
Treatment of Hyperkalemia in the Emergency Department (REVEAL–ED): A
Multicenter, Prospective, Observational Study. The Journal of emergency
medicine 2018;55 (6):741-50
34. LaRue HA, Peksa GD, Shah SC. A comparison of insulin doses for the
treatment of hyperkalemia in patients with renal insufficiency.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
2017;37 (12):1516-22
35. Pierce DA, Russell G, Pirkle Jr JL. Incidence of hypoglycemia in
patients with low eGFR treated with insulin and dextrose for
hyperkalemia. Annals of Pharmacotherapy 2015;49 (12):1322-26
36. Garcia J, Pintens M, Morris A, Takamoto P, Baumgartner L, Tasaka CL.
Reduced versus conventional dose insulin for hyperkalemia treatment.
Journal of Pharmacy Practice 2020;33 (3):262-66
37. Farina N, Anderson C. Impact of dextrose dose on hypoglycemia
development following treatment of hyperkalemia. Therapeutic advances in
drug safety 2018;9 (6):323-29
38. Moratinos J, Reverte M. Effects of catecholamines on plasma
potassium: the role of alpha‐and beta‐adrenoceptors. Fundamental &
clinical pharmacology 1993;7 (3‐4):143-53
39. Liou H-H, Chiang S-S, Wu S-C, et al. Hypokalemic effects of
intravenous infusion or nebulization of salbutamol in patients with
chronic renal failure: comparative study. American journal of kidney
diseases 1994;23 (2):266-71
40. McClure R, Prasad V, Brocklebank J. Treatment of hyperkalaemia using
intravenous and nebulised salbutamol. Archives of disease in childhood
1994;70 (2):126-28
41. Effa E, Webster A. Pharmacological interventions for the management
of acute hyperkalaemia in adults. Nephrology (Carlton, Vic.)
2017;22 (1):5
42. Allon M, Dunlay R, Copkney C. Nebulized albuterol for acute
hyperkalemia in patients on hemodialysis. Annals of internal medicine
1989;110 (6):426-29
43. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and
management. Journal of the American Society of Nephrology
1995;6 (4):1134-42
44. Ngugi N, McLigeyo S, Kayima J. Treatment of hyperkalaemia by
altering the transcellular gradient in patients with renal failure:
effect of various therapeutic approaches. East African medical journal
1997;74 (8):503-09
45. Alfonzo A, Soar J, MacTier R, et al. Clinical practice guidelines:
treatment of acute hyperkalaemia in adults. UK Renal Association 2014
46. Burnell JM, Villamil MF, Uyeno BT, Scribner BH. THE EFFECT IN HUMANS
OF EXTRACELLULAR p H CHANGE ON THE RELATIONSHIP BETWEEN SERUM POTASSIUM
CONCENTRATION AND INTRACELLULAR POTASSIUM. The Journal of clinical
investigation 1956;35 (9):935-39
47. SCHWARZ KC, COHEN BD, LUBASH GD, RUBIN AL. Severe acidosis and
hyperpotassemia treated with sodium bicarbonate infusion. Circulation
1959;19 (2):215-20
48. Fraley DS, Adler S. Correction of hyperkalemia by bicarbonate
despite constant blood pH. Kidney international
1977;12 (5):354-60
49. Mahoney BA, Smith WA, Lo D, Tsoi K, Tonelli M, Clase C. Emergency
interventions for hyperkalaemia. Cochrane database of systematic reviews
2005(2)
50. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate
administration on plasma potassium in terminal renal failure. Kidney
international 1992;41 (2):369-74
51. Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti
G. Management of hyperkalemia in patients with kidney disease: a
position paper endorsed by the Italian Society of Nephrology. Journal of
nephrology 2019;32 (4):499-516
52. Frohnert PP, Johnson WJ, Mueller GJ, Tauxe WN, McCall JT. Resin
treatment of hyperkalemia. II. Clinical experience with a cation
exchange resin (calcium cycle). Translational Research
1968;71 (5):840-46
53. Lillemoe K, Romolo J, Hamilton SR, Pennington L, Burdick JF,
Williams G. Intestinal necrosis due to sodium polystyrene (Kayexalate)
in sorbitol enemas: clinical and experimental support for the
hypothesis. Surgery 1987;101 (3):267-72
54. Lepage L, Dufour A-C, Doiron J, et al. Randomized clinical trial of
sodium polystyrene sulfonate for the treatment of mild hyperkalemia in
CKD. Clinical Journal of the American Society of Nephrology
2015;10 (12):2136-42
55. Nasir K, Ahmad A. Treatment of hyperkalemia in patients with chronic
kidney disease: a comparison of calcium polystyrene sulphonate and
sodium polystyrene sulphonate. Journal of Ayub Medical College
Abbottabad 2014;26 (4):455-8
56. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal
adverse events with sodium polystyrene sulfonate (Kayexalate) use: a
systematic review. The American journal of medicine
2013;126 (3):264. e9-64. e24
57. Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for
serious adverse gastrointestinal events associated with sodium
polystyrene sulfonate use in patients of advanced age. JAMA internal
medicine 2019;179 (8):1025-33
58. Laureati P, Xu Y, Trevisan M, et al. Initiation of sodium
polystyrene sulphonate and the risk of gastrointestinal adverse events
in advanced chronic kidney disease: a nationwide study. Nephrology
Dialysis Transplantation 2019
59. Parks M, Grady D. Sodium polystyrene sulfonate for hyperkalemia.
JAMA Internal Medicine 2019;179 (8):1023-24
60. Sterns RH, Rojas M, Bernstein P, Chennupati S. Ion-exchange resins
for the treatment of hyperkalemia: are they safe and effective? Journal
of the American Society of Nephrology 2010;21 (5):733-35
61. Kamel KS, Schreiber M. Asking the question again: are cation
exchange resins effective for the treatment of hyperkalemia? Nephrology
Dialysis Transplantation 2012;27 (12):4294-97
62. Veltassa [package insert]. Redwood city CR, LLC; 2015.
63. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I-Z.
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium
binder, in a double-blind, placebo-controlled study in patients with
chronic heart failure (the PEARL-HF) trial. European heart journal
2011;32 (7):820-28
64. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum
potassium level in patients with hyperkalemia and diabetic kidney
disease: the AMETHYST-DN randomized clinical trial. Jama
2015;314 (2):151-61
65. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an
individualized dose titration regimen of patiromer to prevent
hyperkalaemia in patients with heart failure and chronic kidney disease.
ESC heart failure 2018;5 (3):257-66
66. Rafique Z, Almasary AN, Singer AJ. Contemporary treatment of
hyperkalemia. Current Emergency and Hospital Medicine Reports
2016;4 (4):219-26
67. Montaperto AG, Gandhi MA, Gashlin LZ, Symoniak MR. Patiromer: a
clinical review. Current medical research and opinion
2016;32 (1):155-64
68. Bhattarai S, Pupillo S, Man Singh Dangol G, Sarac E. Patiromer
Acetate Induced Hypercalcemia: An Unreported Adverse Effect. Case
Reports in Nephrology 2019;2019
69. Wiederkehr MR, Mehta AN, Emmett M. Case report: Patiromer-induced
hypercalcemia. Clinical nephrology. Case Studies 2019;7 :51
70. Lim MA, Sawinski D, Trofe-Clark J. Safety, effectiveness, and
tolerability of patiromer in kidney transplant recipients.
Transplantation 2019;103 (9):e281-e82
71. Rattanavich R, Malone AF, Alhamad T. Safety and efficacy of
patiromer use with tacrolimus in kidney transplant recipients.
Transplant International 2019;32 (1):110-11
72. Clinical trials.gov. Pharmacokinetic Study of Tacrolimus and
Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia
Receiving Patiromer.
73. Bounthavong M, Butler J, Dolan CM, et al. Cost-effectiveness
analysis of patiromer and spironolactone therapy in heart failure
patients with hyperkalemia. Pharmacoeconomics
2018;36 (12):1463-73
74. Astra Zeneca. Lokelma (sodium zirconium cyclosilicate) for oral
suspension: Summary of Product Characteristics,
2018:https://www.ema.europa.eu/en/medicines/human/EPAR/lokelma.
75. Packham DK, Rasmussen HS, Lavin PT, et al. Sodium zirconium
cyclosilicate in hyperkalemia. New England Journal of Medicine
2015;372 (3):222-31
76. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium
zirconium cyclosilicate on potassium lowering for 28 days among
outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
Jama 2014;312 (21):2223-33
77. Spinowitz BS, Fishbane S, Pergola PE, et al. Sodium zirconium
cyclosilicate among individuals with hyperkalemia: a 12-month phase 3
study. Clinical Journal of the American Society of Nephrology
2019;14 (6):798-809
78. Winstead RJ, Demehin M, Yakubu I, et al. Sodium zirconium
cyclosilicate use in solid organ transplant recipients and its effect on
potassium and immunosuppression. Clinical Transplantation
2020;34 (3):e13791
79. Jonathan Zalman SL, Amy Lugo, Leslie Ochs. Sodium zirconium
cyclosilicate: new drug review and cost-minimization analysis. Poster
presented at: ASHP Midyear; December,2019; Las Vegas, NV. 2019
80. Furuya R, Kumagai H, Sakao T, Maruyama Y, Hishida A.
Potassium-lowering effect of mineralocorticoid therapy in patients
undergoing hemodialysis. Nephron 2002;92 (3):576-81
81. Kaisar MO, Wiggins KJ, Sturtevant JM, et al. A randomized controlled
trial of fludrocortisone for the treatment of hyperkalemia in
hemodialysis patients. American journal of kidney diseases
2006;47 (5):809-14
82. Marfo K, Glicklich D. Fludrocortisone therapy in renal transplant
recipients with persistent hyperkalemia. Case reports in transplantation
2012;2012
83. Sivakumar V, Sriramnaveen P, Krishna C, et al. Role of
fludrocortisone in the management of tacrolimus-induced hyperkalemia in
a renal transplant recipient. Saudi Journal of Kidney Diseases and
Transplantation 2014;25 (1):149
84. Çağlayan FB, Koç Y, Baştürk T, et al. Aldosterone Resistance Due to
Tacrolimus: A Case Report. Şişli Etfal Hastanesi Tip Bülteni
2018;52 (4):310-12
85. Nyirenda MJ, Tang JI, Padfield PL, Seckl JR. Hyperkalaemia. Bmj
2009;339
86. Taber DJ, Srinivas TM, Pilch NA, et al. Are thiazide diuretics safe
and effective antihypertensive therapy in kidney transplant recipients?
American journal of nephrology 2013;38 (4):285-91
87. Hou S, McElroy PA, Nootens J, Beach M. Safety and efficacy of
low-potassium dialysate. American Journal of Kidney Diseases
1989;13 (2):137-43
88. Morrison G, Michelson EL, Brown S, Morganroth J. Mechanism and
prevention of cardiac arrhythmias in chronic hemodialysis patients.
Kidney international 1980;17 (6):811-19
89. Dolson GM, Adrogue HJ. Low dialysate [K+] decreases efficiency
of hemodialysis and increases urea rebound. Journal of the American
Society of Nephrology 1998;9 (11):2124-28
90. Capdevila M, Martinez Ruiz I, Ferrer C, et al. The efficiency of
potassium removal during bicarbonate hemodialysis. Hemodialysis
International 2005;9 (3):296-302
91. Gutzwiller J, Schneditz D, Huber A, Schindler C, Garbani E, Zehnder
C. Increasing blood flow increases kt/V (urea) and potassium removal but
fails to improve phosphate removal. Clinical nephrology
2003;59 (2):130
Table 1. Food Rich in Potassium Content